Highly cited paper on women and heart disease retracted for failure to replicate

jcemA highly cited study examining the risks of heart disease in post-menopausal women with symptoms of polycystic ovary syndrome (PCOS) has been retracted by its authors because they could not replicate the results.

Here’s the retraction notice for the paper, which appeared in the Journal of Clinical Endocrinology & Metabolism: Continue reading Highly cited paper on women and heart disease retracted for failure to replicate

Former Florida ob-gyn prof notches eighth retraction

University of Florida
University of Florida

Nasser Chegini, the former University of Florida professor currently under investigation by the Office of Research Integrity (ORI), has now had eight papers retracted.

The eighth paper, in the journal Reproductive Biology and Endocrinology, is about the effect of a compound used during fertility treatments on Smads, signaling molecules that carry messages from TGF-beta receptors to the nucleus. It’s being retracted disappeared due to the discovery of data that “have been fabricated or falsified by the last author” — namely, Chegini.

Here’s more from the notice for “Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells:” Continue reading Former Florida ob-gyn prof notches eighth retraction

Gynecologic cancer researcher earns eighth retraction

Screen Shot 2015-04-02 at 5.50.31 PMNoriyuki Takai, a gynecologic cancer researcher in Japan, has notched one more retraction — bringing the total to eight — due to figures that were “processed inappropriately” and did “not accurately report the original data.”

According to the notice, Takai alone put the figures together in the 2006 Oncology paper, which tested a histone deacetylase inhibitor on endometrial and ovarian cancer cell lines. The team is part of the department of obstetrics and gynecology at Oita University in Japan.

Takai lost four papers in 2013 in Cancer Letters, and three papers in 2012 in Gynecologic Oncology, also due to issues with figures.

Continue reading Gynecologic cancer researcher earns eighth retraction

Ob-gyn prof up to 7 retractions, latest due to “substantial data misrepresentation”

University of Florida
University of Florida

Two more retractions have popped up for Nasser Chegini, the former University of Florida professor currently under investigation by the Office of Research Integrity (ORI).

Both retractions appear in the Journal of Clinical Endocrinology & Metabolism. The notices indicate that an investigation report from the University of Florida “found substantial data misrepresentation” in two JCEM articles about Smads, signaling molecules that carry messages from TGF-beta receptors to the nucleus.

Here’s the notice for “The Expression of Smads in Human Endometrium and Regulation and Induction in Endometrial Epithelial and Stromal Cells by Transforming Growth Factor-Beta” (cited 28 times, according to Thomson Scientific’s Web of Knowledge):

Continue reading Ob-gyn prof up to 7 retractions, latest due to “substantial data misrepresentation”

Thalidomide paper retracted for lab error

fertstertResearchers at the University of Pittsburgh have retracted a paper on using thalidomide, which led to an estimated 10,000 birth defects by the time the drug was pulled from the market in 1961, to prevent chemo-induced sterility.

Alkylating agents, which prevent DNA replication in cells, are a commonly-used cancer treatment. Unfortunately they also damage the ovaries and testes, sometimes causing infertility. The University of Pittsburgh scientists published a paper in Elsevier journal Fertility and Sterility in 2011 that suggested thalidomide, which causes severe birth defects when used during pregnancy, might help protect ovaries during chemo.

However, according to the notice, the authors tried and failed to replicate their results. They had two separate scientists who were not authors take a look at the results; everyone agreed that the original study incorrectly reported the number of primordial follicles, the precursor to mature eggs.

Here’s the notice for “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”: Continue reading Thalidomide paper retracted for lab error

Three more retractions appear for Florida ob-gyn under investigation

University of Florida
Nasser Chegini via University of Florida

Two Oxford journals have now put out three more retractions for ob-gyn and former University of Florida professor Nasser Chegini, who has been under ORI investigation since at least 2012. That makes a total of five retractions, by our count.

Here is the notice for “The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression” in Molecular Human Reproduction: Continue reading Three more retractions appear for Florida ob-gyn under investigation

Authors retract HER-2 endometrial cancer paper for 2x publication

OGSFile this one under strange excuses.

A cancer paper was retracted on September 17 for a double publication. According to the notice in which the authors admit to duplicating the “opening to the readers,” which we assume is the introduction, there was no need to cite the article “because it had not yet been printed at that time.”

Here’s the notice for “The effect of HER-2 polymorphism according to age on the risk and pathologic feature of endometrial cancer”: Continue reading Authors retract HER-2 endometrial cancer paper for 2x publication

Second retraction appears for former University of Florida ob-gyn subject to ORI probe

University of Florida
Chegini, via University of Florida

Nasser Chegini, an ob-gyn formerly on the faculty at the University of Florida who has been the subject of an Office of Research Integrity (ORI) inquiry for several years, has a second retraction.

Chegini is suspected of having used bogus data in some of his work — research backed in part by some $4 million in federal funding.

The new retraction involves a 2008 paper in Reproductive Sciences on which Chegini was senior author. Here’s the notice: Continue reading Second retraction appears for former University of Florida ob-gyn subject to ORI probe

Patient mix-up sinks prenatal supplement paper

This one seems like an honest mistake: a paper on dietary supplements during pregnancy has been retracted based on an error in data recording.

In the BMC Pregnancy & Childbirth paper, “Folic acid supplementation, dietary folate intake during pregnancy and risk for spontaneous preterm delivery: a prospective observational cohort study,” women for whom the researchers had no data on folic acid supplementation were classified as taking no supplements. Despite the error, the authors claim the overall conclusion remains the same: taking folic acid supplements didn’t protect women from preterm deliveries.

Here’s the retraction notice: Continue reading Patient mix-up sinks prenatal supplement paper

Editor in chief steps down after being found plagiarizing in her own journal

diab met syndImagine you were a cop, sitting in your squad car at the side of the road with a radar gun, when you clock someone speeding. You turn on your lights, pull the speedster over to the side of the road, and walk to her driver’s side window.

Just as you say “Driver’s license and registration, please,” you realize the driver is your squad captain. Oops.

That must have been something like what it was like — with plagiarism detection software sitting in for the radar gun — for the co-editor-in-chief of Diabetology & Metabolic Syndrome when he realized that Marilia de Brito Gomes, the other co-editor-in-chief, had published two papers in their journal that contained plagiarized passages.

Here’s the notice for “Historical facts of screening and diagnosing diabetes in pregnancy:” Continue reading Editor in chief steps down after being found plagiarizing in her own journal